Ulysses Diversified Holding
Ulysses Diversified Holdings is a company that develops, finances, and supports high-growth businesses through strategic investments and professional assistance. In addition to its investment activities, Ulysses is involved in the security and surveillance sector, providing monitoring services that enable customers to observe the activities and interactions of children via the internet. This dual focus on fostering business growth and enhancing security solutions positions Ulysses Diversified Holdings as a versatile entity in the market.
Top Stages
4 past transactions
Alloy Therapeutics
Series C in 2021
Alloy Therapeutics is a biotechnology company based in Waltham, Massachusetts, founded in 2017. The company focuses on democratizing access to essential drug discovery platforms and services, primarily through its Alloy-Gx platform. This innovative platform features a royalty-free suite of immunocompetent transgenic mice that facilitate in vivo human antibody discovery. Alloy Therapeutics has developed humanized transgenic antibody discovery technology, which offers broad, non-exclusive access to drug discovery tools, allowing scientists to engage in their antibody projects more efficiently and effectively. The company's mission is to enhance the drug discovery process by providing accessible and advanced resources for researchers in the field.
WelbeHealth
Series C in 2020
WelbeHealth serves frail seniors through its PACE (Program of All-Inclusive Care for the Elderly) model, providing comprehensive medical and social care. This enables participants to live better, longer, and more independently. The company coordinates various aspects of care, including medical appointments, therapy sessions, transportation, meals, and personal care services.
Compass Therapeutics
Series A in 2018
Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.
WelbeHealth
Series B in 2018
WelbeHealth serves frail seniors through its PACE (Program of All-Inclusive Care for the Elderly) model, providing comprehensive medical and social care. This enables participants to live better, longer, and more independently. The company coordinates various aspects of care, including medical appointments, therapy sessions, transportation, meals, and personal care services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.